Novocure (NASDAQ: NVCR) is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. Headquartered in Jersey Isle, Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland, Germany and Japan and a research center in Haifa, Israel.